Three independent discounted-cash-flow-style models value Incyte Genomics Inc every trading day. 0 of 3 currently price INCY above its market price.
| Free Cash Flow model | $-38.65 |
| Excess Profit model | $29.08 |
| Residual Earnings model | $7.15 |
| Dividend Discount model | — |
| Piotroski F-Score | 4 / 9 |
| Return on invested capital | +8.8% |
| Net debt / EBITDA | -4.4× |
| Gross margin | +93.1% |
| Revenue CAGR | +11.5% |
| Cash conversion | 0.8× |
| Dividend yield | — |
| Buyback yield | -0.7% |
These are StockKitty's default assumptions. In the app, the models recompute live as you adjust growth, discount rates, and margins — and the AI explains the bull case, bear case, and quality picture.
Open INCY in StockKitty